This study was conducted by Fang Hai and team from Peking University and published in Human Vaccines & Immunotherapeutics, assessing the potential health impact and cost-effectiveness of introducing Rotateq, Rotarix, and Lanzhou lamb rotavirus vaccine (LLR) into China’s national immunization program. A decision-tree Markov model was adopted to follow the 2019 birth cohort. The study concluded introducing the RV vaccine in China’s NIP is expected to be cost-effective compared to the GDP per capita. Reducing vaccine prices and adopting vaccines with better efficacy would be the future focus.
Independent and joint associations of sex and birth order with non‑national immunization program vaccine coverage among Chinese children: a cross-sectional analysis
This research conducted by Prof. Xiaolin Xu and team from Zhejiang University, was published in the International Journal for Equity in Health. Based on a 2022 survey in Zhejiang and Henan provinces, the study analyzed the independent and joint associations of sex and birth order with non-National Immunization Program (non-NIP) vaccine coverage among Chinese children aged 1–6. The results showed that birth order was an important factor influencing vaccination, with the lowest coverage observed among later-born girls, particularly third or later-born daughters.
